Triptorelin is a hormone treatment for prostate cancer or early breast cancer.
You might have triptorelin for prostate cancer that is:
● Advanced (spread to other parts of the body)
● locally advanced with or without surgery
You might have triptorelin for early breast cancer with other hormone treatments .
You might also have triptorelin as part of a clinical trial for prostate or breast cancer.
Triptorelin is a potent repressor of gonadotropin secretion when given continuously and in therapeutic doses. Following the first administration, there is a transient surge in circulating levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone and estradiol. After chronic and continuous administration, usually two to four weeks after initiation of therapy, a sustained decrease in LH and FSH secretion and marked reduction of testicular and ovarian steroidogenesis is observed. In men, a reduction of serum testosterone concentration to a level typically seen in surgically castrated men is obtained. Consequently, the result is that tissues and function that depend on these hormones for maintenance become quiescent. These effects are usually reversible after cessation of therapy.
